My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
Res 2016-077/approving an administrative services agreement with United Healthcare Services, Inc. for the provision of medical, pharmacy, dental, flexible spending accounts (fsa), retiree, online enrollment tool and cobra benefits administration in a tot
San-Marcos
>
City Clerk
>
03 Resolutions
>
2010's
>
2016
>
Res 2016-077/approving an administrative services agreement with United Healthcare Services, Inc. for the provision of medical, pharmacy, dental, flexible spending accounts (fsa), retiree, online enrollment tool and cobra benefits administration in a tot
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
7/18/2016 2:07:35 PM
Creation date
7/18/2016 1:30:22 PM
Metadata
Fields
Template:
City Clerk
City Clerk - Document
Resolutions
City Clerk - Type
Approving
Number
2016-77
Date
6/21/2016
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
52
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
Show annotations
View images
View plain text
HEMOPHILIA <br />MONONINE <br />29.6% <br />ONCOLOGY - ORAL <br />NEXAVAR <br />12.5% <br />HEMOPHILIA <br />NOVOEIGHT <br />24.8% <br />ONCOLOGY - ORAL <br />POMALYST <br />13.0% <br />HEMOPHILIA <br />NOVOSEVEN RT <br />34.1% <br />ONCOLOGY - ORAL <br />REVLIMID <br />9.6% <br />HEMOPHILIA <br />PROFILNINE <br />13.4% <br />ONCOLOGY - ORAL <br />SPRYCEL <br />14.5% <br />HEMOPHILIA <br />PROFILNINE SD <br />13.4% <br />ONCOLOGY - ORAL <br />STIVARGA <br />13.5% <br />HEMOPHILIA <br />RECOMBINATE <br />37.4% <br />ONCOLOGY - ORAL <br />SUTENT <br />13.5% <br />HEMOPHILIA <br />RIXUBIS <br />7.3% <br />ONCOLOGY-ORAL <br />TAFINLAR <br />11.4% <br />HEMOPHILIA <br />TRETTEN <br />13.5% <br />ONCOLOGY - ORAL <br />TARCEVA <br />13.5% <br />HEMOPHILIA <br />WILATE <br />13.5% <br />ONCOLOGY - ORAL <br />TASIGNA <br />13.5% <br />HEMOPHILIA <br />XYNTHA <br />13.5% <br />ONCOLOGY - ORAL <br />TEMODAR <br />14.2% <br />HEPATITIS B <br />ADEFOVIR DIPIVOXIL <br />13.2% <br />ONCOLOGY - ORAL <br />TEMOZOLOMIDE <br />14.2% <br />HEPATITIS B <br />BARACLUDE <br />13.2% <br />ONCOLOGY - ORAL <br />THALOMID <br />14.0% <br />HEPATITIS B <br />ENTECAVIR <br />13.2% <br />ONCOLOGY-ORAL <br />TRETINOIN <br />18.1% <br />HEPATITIS B <br />EPIVIR HBV <br />12.2% <br />ONCOLOGY-ORAL <br />TYKERB <br />14.0% <br />HEPATITIS B <br />HEPSERA <br />13.2% <br />ONCOLOGY - ORAL <br />VOTRIENT <br />12.6% <br />HEPATITIS B <br />LAMIVUDINE HBV <br />12.2% <br />ONCOLOGY-ORAL <br />XALKORI <br />13.5% <br />HEPATITIS B <br />TYZEKA <br />13.2% <br />ONCOLOGY-ORAL <br />XELODA <br />13.2% <br />HEPATITIS C <br />COPEGUS <br />14.2% <br />ONCOLOGY - ORAL <br />XTANDI <br />13.5% <br />HEPATITIS C <br />DAKLINZA <br />13.5% <br />ONCOLOGY-ORAL <br />ZELBORAF <br />12.2% <br />HEPATITIS C <br />HARVONI <br />14.5% <br />ONCOLOGY-ORAL <br />ZOLINZA <br />14.2% <br />HEPATITIS C <br />INCIVEK <br />13.5% <br />ONCOLOGY-ORAL <br />ZYDELIG <br />13.5% <br />HEPATITIS C <br />MODERIBA <br />13.5% <br />ONCOLOGY - ORAL <br />ZYKADIA <br />13.0% <br />HEPATITIS C <br />OLYSIO <br />13.5% <br />ONCOLOGY-ORAL <br />ZYTIGA <br />13.5% <br />HEPATITIS C <br />PEGASYS <br />16.4% <br />ONCOLOGY - <br />TOPICAL <br />TARGRETIN <br />13.5% <br />HEPATITIS C <br />PEGINTRON <br />14.2% <br />ONCOLOGY - <br />TOPICAL <br />VALCHLOR <br />7.8% <br />HEPATITIS C <br />REBETOL <br />16.5% <br />OSTEOPOROSIS <br />FORTEO <br />13.2% <br />HEPATITIS C <br />RIBAPAK <br />53.7% <br />PARKINSONS <br />DISEASE <br />APOKYN <br />11.5% <br />HEPATITIS C <br />RIBASPHERE <br />57.1% <br />PULMONARY <br />DISEASE <br />ESBRIET <br />13.5% <br />HEPATITIS C <br />RIBASPHERE RIBAPAK <br />53.7% <br />PULMONARY <br />DISEASE <br />OFEV <br />12.5% <br />HEPATITIS C <br />RIBATAB <br />53.7% <br />PULMONARY <br />HYPERTENSION <br />ADCIRCA <br />12.7% <br />HEPATITIS C <br />RIBAVIRIN <br />57.1% <br />PULMONARY <br />HYPERTENSION <br />ADEMPAS <br />12.5% <br />HEPATITIS C <br />SOVALDI <br />13.5% <br />PULMONARY <br />HYPERTENSION <br />LETAIRIS <br />12.7% <br />HEPATITIS C <br />VICTRELIS <br />13.5% <br />PULMONARY <br />HYPERTENSION <br />OPSUMIT <br />12.7% <br />HEPATITIS C <br />VIEKIRA PAK <br />13.5% <br />PULMONARY <br />HYPERTENSION <br />ORENITRAM <br />12.5% <br />HIV <br />ABACAVIR <br />14.2% <br />PULMONARY <br />HYPERTENSION <br />REVATIO <br />10.9% <br />HIV <br />ABACAVIR- LAMIVUDINE- <br />ZIDOVUDINE <br />14.2% <br />PULMONARY <br />HYPERTENSION <br />SILDENAFIL <br />10.9% <br />HIV <br />APTIVUS <br />14.3% <br />PULMONARY <br />HYPERTENSION <br />SILDENAFIL <br />CITRATE <br />10.9% <br />HIV <br />ATRIPLA <br />13.3% <br />PULMONARY <br />HYPERTENSION <br />TRACLEER <br />12.7% <br />HIV <br />COMBIVIR <br />13.5% <br />PULMONARY <br />HYPERTENSION <br />TYVASO <br />3.7% <br />41 <br />
The URL can be used to link to this page
Your browser does not support the video tag.